Key Statistics
About Larimar Therapeutics, Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Analyst Ratings
View All →| Date | Firm | Rating |
|---|---|---|
| Oct 2, 2025 | Oppenheimer | |
| Sep 30, 2025 | Wedbush | |
| Sep 30, 2025 | Baird |